84. サルコイドーシス Sarcoidosis Clinical trials / Disease details


臨床試験数 : 149 薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00926627
(ClinicalTrials.gov)
April 200922/6/2009Safety and Efficacy Study of Bosentan in Progressive Pulmonary SarcoidosisA Prospective Randomized, Double Blind, Placebo-controlled, Safety and Efficacy Study of Bosentan as add-on Therapy in Progressive Pulmonary SarcoidosisSarcoidosis;Pulmonary HypertensionDrug: bosentan;Drug: placeboDaniel DobererNULLTerminated18 Years70 YearsBoth32Phase 2Austria
2EUCTR2007-005117-18-AT
(EUCTR)
03/04/200804/03/2008Safety and efficacy study of bosentan in progressive pulmonary sarcoidosis - BOPSACSafety and efficacy study of bosentan in progressive pulmonary sarcoidosis - BOPSAC Progressive pulmonary sarcoidosis
MedDRA version: 9.1;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis
Trade Name: Tracleer
Product Name: Bosentan
Medical University of Vienna, Department of Clinical PharmacologyNULLNot RecruitingFemale: yes
Male: yes
Austria
3NCT00581607
(ClinicalTrials.gov)
April 200826/12/2007Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary HypertensionDouble Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary HypertensionSarcoidosis;Pulmonary Arterial HypertensionDrug: Bosentan;Drug: PlaceboUniversity of CincinnatiActelionCompleted18 YearsN/ABoth43Phase 2/Phase 3United States
4EUCTR2006-005361-19-GB
(EUCTR)
09/03/200717/12/2006Evaluation of the efficacy of the dual endothelin 1 receptor antagonist Bosentan in the treatment of Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and in the treatment of Pulmonary Hypertension secondary to sarcoidosisEvaluation of the efficacy of the dual endothelin 1 receptor antagonist Bosentan in the treatment of Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and in the treatment of Pulmonary Hypertension secondary to sarcoidosis Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and secondary to Sarcoid Patients devolop pulmonary hypertension for various reasons, two common causes are Chronic Obstructive Pulmonary disease and Sarcoid. Once developed it may go on to cause right heart failure and severe breathlessness and eventually death. We believe that the use of bosentan may lower the pulmonary hypertension and improve symptoms.
MedDRA version: 8.1;Level: LLT;Classification code 10037400;Term: Pulmonary hypertension
Trade Name: Tracleer
Product Name: tracleer
INN or Proposed INN: Bosentan monohydrate
St Georges HospitalNULLNot Recruiting Female: yes
Male: yes
45 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesUnited Kingdom